Company Information

RNA Disease Diagnostics (RNADD) was formed to create a best-in-class rapid, accurate and low-cost molecular diagnostic technology platform that will democratize point of care testing and contribute to the prevention of infectious disease transmission and to better the health of the citizens of the world. The Company plans to leverage its proprietary Electrochemical and AntiSense Oligonucleotide (ASO) RNA molecular diagnostic platform across multiple diseases. Working with the University of Maryland, Baltimore (UMB) and the University of Maryland, Baltimore County (UMBC) RNADD has secured an exclusive global license to this cutting-edge molecular sensor technology.

RNADD’s initial focus is to develop and deploy its proprietary molecular diagnostic technology at the Point Of Care (POC). The Company operates out of New York, California and Toronto, Canada.

Request the RNADD Company Overview Presentation

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Mike Kaufmann, former Cardinal Health CEO, joins RNA Disease Diagnostics, Inc. Board of Directors

October 3, 2023

Mike C. Kaufmann recently joined the Board of Directors of RNA Disease Diagnostics, Inc. (RNADD). Mike is a former Fortune 15 CEO and CFO, and an active advocate and executive speaker on leadership and diversity, equity, and inclusion (DE&I).

Read MoreRead More

RNA Disease Diagnostics Expands Board of Directors

April 4, 2022

RNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care (“POC”) and home-use infectious disease detection, announced today the appointments of its Chief Scientific Advisor, Professor Dipanjan Pan, M.S., Ph.D., and its President, John W. Erickson, Jr., to the Company’s Board of Directors.

Read MoreRead More